Ozempic is probably the most well-known medicine today. But interestingly, the reason it was invented is not the reason it became popular. Originally a medicine for diabetes, today Ozempic is used by millions of people around the world to aid in weight loss. But does all this come without side effects? We need to talk about Ozempic. BLACK FRIDAY at LOOS! Dress the Universe with up to 30% OFF! https://bit.ly/CamisetasLoos Become a member of our channel to help keep the videos on the air! http://youtube.com/cienciatododia/join Business email: [email protected] My social networks: /pedroloos / pedroloos / opedroloos Our podcast: https://open.spotify.com/show/59fUC0C... Chapters 0:00 - 1:15 Ozempic: from diabetes medicine to addiction treatment? 1:15 - 3:35 How does Ozempic work? 3:35 - 5:32 The impact of Ozempic 5:32 - 8:57 Ozempic and weight loss 8:57 - 12:37 Ozempic and addiction treatment: a new horizon? Sources and Further Reading: Astrup, A. Reflections on the discovery GLP-1 as a satiety hormone: Implications for obesity therapy and future directions. Eur J Clin Nutr 78, 551–556 (2024). https://doi.org/10.1038/s41430-024-01... Greenhill, C. Brain–immune networks: a role for GLP1 receptor. Nat Rev Endocrinol 20, 125 (2024). https://doi.org/10.1038/s41574-024-00... Baggio LL, Drucker DJ. Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight. J Clin Invest. 2014 Oct;124(10):4223-6. doi: 10.1172/JCI78371. https://www.ncbi.nlm.nih.gov/books/NB... https://www.npr.org/sections/health-s... Leslie M. Hot weight loss drugs tested against addiction. Science. 2023 Sep;381(6661):930-931. doi: 10.1126/science.adk5720. Rubin R. Could GLP-1 Receptor Agonists Like Semaglutide Treat Addiction, Alzheimer Disease, and Other Conditions? JAMA. 2024;331(18):1519–1521. doi:10.1001/jama.2024.1017 Qeadan F, McCunn A, Tingey B. The association between glucose-dependent insulinotropic polypeptide and/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: A real-world data analysis. Addiction. 2024. https://doi.org/10.1111/add.16679 Egecioglu E, Engel JA, Jerlhag E. The glucagon-like peptide 1 analogue, exendin-4, attenuates the rewarding properties of psychostimulant drugs in mice. PLoS One. 2013 Jul 16;8(7):e69010. doi: 10.1371/journal.pone.0069010. PMID: 23874851; PMCID: PMC3712951. Herman RJ, Hayes MR, Audrain-McGovern J, Ashare RL, Schmidt HD. Liraglutide attenuates nicotine self-administration as well as nicotine seeking and hyperphagia during withdrawal in male and female rats. Psychopharmacology (Berl). 2023 Jun;240(6):1373-1386. doi: 10.1007/s00213-023-06376-w. Epub 2023 May 2. PMID: 37129617; PMCID: PMC11088902. Chuong V, Farokhnia M, Khom S, Pince CL, Elvig SK, Vlkolinsky R, Marchette RC, Koob GF, Roberto M, Vendruscolo LF, Leggio L. The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission. JCI Insight. 2023 Jun 22;8(12):e170671. doi: 10.1172/jci.insight.170671. PMID: 37192005; PMCID: PMC10371247.